Recurrent hypoglycaemia in a type 2 diabetes patient - Diagnostic difficulties

Archives of Medical Science

Volumn 6, Issue 1, 2010, Pages 126-129

  Grycewicz, Joanna ^a,b   Ścibór, Zdzisława ^a,b   Ćwikła, Jarosław B ^c   Lewiński, Andrzej ^a,b   Cypryk, Katarzyna ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

Author keywords

Hypoglycaemia; Insulinoma; Neuroendocrine tumour; Type 2 diabetes

Indexed keywords

OCTREOTIDE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC TEST; FEMALE; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INSULINOMA; NEUROENDOCRINE TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RECURRENT DISEASE;

EID: 77949405767     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.13520     Document Type: Article

References (11)

1. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161: 1653-9.
2. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66: 711-9.
3. Mittendorf EA, Liu YC, McHenry CR. Giant insulinoma: case report and review of the literature. J Clin Endocrinol Metab 2005; 90: 575-80.
4. Nikfarjam M, Warshaw AL, Axelrod L, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008; 247: 165-72.
5. Ramage JK, Davies AH, Ardill J, et al. UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 Suppl 4: iv1-16.
6. Furrer J, Hättenschwiler A, Komminoth P, Pfammatter T, Wiesli P. Carcinoid syndrome, acromegaly, and hypoglycemia due to an insulin-secreting neuroendocrine tumor of the liver. J Clin Endocrinol Metab 2001; 86: 2227-30.
7. Usukura M, Yoneda T, Oda N, et al. Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J 2007; 54: 95-101.
8. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88: 5353-60.
9. Gama R, Marks V, Wright J, Teale JD. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol (Oxf) 1995; 43: 117-20.
10. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 1997; 73: 640-1.
11. Kane LA, Grant CS, Nippoldt TB, Service FJ. Insulinoma in a patient with NIDDM. Diabetes Care 1993; 16: 1298-300.